Oligodendroglioma
Symptoms, Doctors, Treatments, Advances & More

Oligodendroglioma Overview

Save information for later
Sign Up

Learn About Oligodendroglioma

View Main Condition: Brain Tumor

What is the definition of Oligodendroglioma?
Oligodendroglioma is a type of brain tumor that develops from oligodendrocytes, which are specialized cells that protect neurons (nerve cells). Oligodendroglioma can occur in the brain and spinal cord.  Oligodendrogliomas are also classified as either Grade 2 or Grade 3. Grade 2 oligodendrogliomas do not spread as aggressively as Grade 3 and are less likely to cause severe symptoms. 
What are the causes of Oligodendroglioma?
The cause of oligodendrogliomas is still unknown. However, oligodendrogliomas generally tend to be more common in adults than children. Men are also more likely to develop oligodendrogliomas than women.
What are the symptoms of Oligodendroglioma?
Symptoms for oligodendroglioma primarily depend on the size and location of the tumor. Common symptoms include seizures, headaches, short-term memory issues, personality changes, and weakness on one side of the body.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Oligodendroglioma?
Treatment for oligodendroglioma may include surgery, radiation therapy, and/or chemotherapy. Surgery to remove the tumor is generally the first step in treating oligodendroglioma. Depending on the tumor's location, surgery may be able to entirely remove smaller oligodendrogliomas. However, if a tumor is located near a sensitive area in the brain, surgery may not be possible at all. Radiation therapy often follows surgery for the treatment of oligodendrogliomas. Radiation therapy involves the use of high-energy beams, including X-rays or protons, to destroy tumor cells. Chemotherapy involves the use of drugs, either taken orally or injected through a vein, to kill tumor cells. Chemotherapy is often used in combination with radiation therapy.
Who are the top Oligodendroglioma Local Doctors?
Elite in Oligodendroglioma
Dr. Jennie W. Taylor
Neurosurgery | Neurology
Elite in Oligodendroglioma
Dr. Jennie W. Taylor
Neurosurgery | Neurology
Referral may be required

Brain Tumor Center

400 Parnassus Ave., Eighth Floor, 
San Francisco, CA 
415-353-7500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jennie Taylor is a Neurosurgery specialist and a Neurologist practicing medicine in San Francisco, California. Dr. Taylor is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Glioma, Astrocytoma, Glioblastoma, and Brain Tumor. Dr. Taylor is board certified in American Board Of Psychiatry/Neurology-Neurology, Neurology. Dr. Taylor is currently accepting new patients.

Elite in Oligodendroglioma
Elite in Oligodendroglioma
Referral may be required

Northwell Health Ambulatory Surgery At The Center For Advanced Medicine

450 Lakeville Road, Entrance F, 
Lake Success, NY 
516-941-1260
Languages Spoken:
English, Hebrew
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Schulder is a Neurosurgery provider practicing medicine in Lake Success, New York. Dr. Schulder is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. He is also highly rated in 32 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Brain Tumor, Gamma Knife Radiosurgery, and Awake Craniotomy. Dr. Schulder is board certified in American Board Of Neurological Surgery. Dr. Schulder is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Oligodendroglioma
Elite in Oligodendroglioma
Referral may be required

Adolescent And Young Adult Neuro-Oncology Clinic

400 Parnassus Ave # 8, 
San Francisco, CA 
415-353-7500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John De Groot is a Neurologist practicing medicine in San Francisco, California. Dr. De Groot is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

View All Doctors
What is the outlook (prognosis) for Oligodendroglioma?
The prognosis for oligodendroglioma is very good with current treatments. When the tumor can be removed, survival rates are over 90%. If the tumor can not be removed but radiation therapy is used, survival rates are between 80-90%.
How do I prevent Oligodendroglioma?
There is no known way to prevent oligodendrogliomas. However, if you develop any symptoms common to oligodendroglioma, it is recommended to make an appointment with your doctor to be properly diagnosed.
What are the latest Oligodendroglioma Clinical Trials?
A Phase 2, Single Arm, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Vorasidenib in Pediatric Participants Aged 12 to < 18 Years Old With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
A Phase 2, Single Arm, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Vorasidenib in Pediatric Participants Aged 12 to < 18 Years Old With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: The objective of this study is to evaluate the safety, tolerability, efficacy profile, and effect on growth and development of vorasidenib in pediatric participants aged 12 to \< 18 years old with grade 2 glioma with an IDH1 or IDH2 mutation. The study includes a screening period, a treatment period consisting of continuous 28-day cycles of treatment, a safety follow-up period and a long-term foll...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Who is this study for: Children with recurrent or refractory cerebellar brain tumors
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Biological
Study Drug: G207
Study Phase: Phase 1

Summary: This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD

View All Clinical Trials
What are some Advocacy Organizations?
keep-punching-brain-cancer

Keep Punching supports patients, healthcare providers, and researchers in their fight to prevent and eradicate brain cancer and minimize treatment-related side effects that may adversely impact function and comfort.